Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
0(0%)
Results Posted
44%(4 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_4
1
9%
Ph phase_1
4
36%
Ph phase_2
4
36%
Ph phase_3
1
9%

Phase Distribution

4

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
4(40.0%)
Phase 2Efficacy & side effects
4(40.0%)
Phase 3Large-scale testing
1(10.0%)
Phase 4Post-market surveillance
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Active(1)
Completed(9)
Terminated(1)

Detailed Status

Completed9
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (40.0%)
Phase 24 (40.0%)
Phase 31 (10.0%)
Phase 41 (10.0%)

Trials by Status

completed982%
not_yet_recruiting19%
terminated19%

Recent Activity

0 active trials
Showing 5 of 11
not_yet_recruitingphase_4

Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)

NCT07357103
completedphase_1

Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma

NCT03730363
terminatedphase_2

0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma

NCT00729807
completedphase_3

Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study

NCT01360762
completedphase_1

Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults

NCT00078559
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07357103Phase 4

Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)

Not Yet Recruiting
NCT03730363Phase 1

Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma

Completed
NCT00729807Phase 2

0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma

Terminated
NCT01360762Phase 3

Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study

Completed
NCT00078559Phase 1

Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults

Completed
NCT00014911Phase 2

Islet Transplantation for Type 1 Diabetes

Completed
NCT02669706

Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia

Completed
NCT00002524Phase 2

Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma

Completed
NCT00810953Phase 1

A Safety Study Using Pentamidine in Patients With Pancreatic Cancer Undergoing Standard Therapy

Completed
NCT00809796Phase 1

A Safety Study of Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Chemotherapy as Second-line and/or Third-line Treatment

Completed
NCT00803933Phase 2

Trial of DB289 for the Treatment of Stage I African Trypanosomiasis

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11